Radiation-Induced Nausea Supportive Care in Pediatric Oncology irantextbook.ir 93df

of chemotherapy induced nausea and vomiting CINV. J Pediatr Hematol Oncol 32:e268–e271 Corapcioglu F, Sarper N 2005 A prospective random- ized trial of the antiemetic effi cacy and cost- effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer. Pediatr Hematol Oncol 22:103–114 Croom KF, Keating GM 2006 Metopimazine. Am J Cancer 5:123–136 Culy CR, Bhana N, Plosker GL 2001 Ondansetron: a review of its use as an antiemetic in children. Paediatr Drugs 3:441–479 De Leon A 2006 Palonosetron Aloxi: a second- generation 5-HT 3 receptor antagonist for chemotherapy- induced nausea and vomiting. Proc Bayl Univ Med Cent 19:413–416 Dick GS, Meller ST, Pinkerton CR 1995 Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child 73:243–245 Dodds LJ 1985 The control of cancer chemotherapy- induced nausea and vomiting. J Clin Hosp Pharm 10:143–166 Dupuis LL, Taddio A, Kerr EN et al 2006 Development and validation of a pediatric nausea assessment tool PeNAT for use by children receiving antineoplastic agents. Pharmacotherapy 26:1221–1231 Dupuis LL, Milne-Wren C, Cassidy M et al 2010 Symptom assessment in children receiving cancer therapy: the parents’ perspective. Support Care Cancer 18:281–299 Dupuis LL, Boodhan S, Sung L et al 2011 Guideline for the classifi cation of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57:191–198 Dupuis LL, Boodhan S, Holdsworth M et al 2013 Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediat- ric cancer patients. Pediatr Blood Cancer 60: 1073–1082 Eisenberg P, Figueroa-Vadillo J, Zamora R et al 2003 Improved prevention of moderately emetogenic che- motherapy induced nausea and vomiting with palono- setron, a pharmacologically novel 5-HT3 receptor antagonist: results of a Phase III, single-dose trial ver- sus dolasetron. Cancer 98:2473–2482 Ettinger D, Akerley W, Benson A et al 2012 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Antiemesis, V.1.2012 http: www.nccn.orgprofessionalsphysician_glsPDFanti- emesis.pdf Ezzo J, Streitberger K, Schneider A 2006 Cochrane sys- tematic reviews examine P6 acupuncture-point stimu- lation for nausea and vomiting. J Altern Complement Med 12:489–495 Feyer PC, Maranzano E, Molassiotis A 2005 Radiotherapy- induced nausea and vomiting RINV: antiemetic guide- lines. Support Care Cancer 13:122–128 Figueroa-Moseley C, Jean-Pierre P, Roscoe JA et al 2007 Behavioral interventions in treating anticipa- tory nausea and vomiting. J Natl Compr Canc Netw 5:44–50 Gebbia V, Cannata G, Testa A et al 1994 Ondansetron versus granisetron in the prevention of chemotherapy- induced nausea and vomiting. Results of a prospective randomized trial. Cancer 74:1945–1952 Geling O, Eichler HG 2005 Should 5- hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294 Gore L, Chawla SP, Petrilli AS et al 2009 Aprepitant in adolescent patients for prevention of chemotherapy- induced nausea and vomiting: a randomized, double- blind, placebo-controlled study of effi cacy and tolerability. Pediatr Blood Cancer 52:242–247 Gralla R, Lichinitser M, Van Der Vegt S et al 2003 Palonosetron improves prevention of chemotherapy- induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577 Grunberg SM, Deuson RR, Mavros P et al 2004 Incidence of chemotherapy-induced nausea and eme- sis after modern antiemetics. Cancer 100:2261–2268 Grunberg SM, Warr D, Gralla RJ et al 2010 Evaluation of new antiemetic agents and defi nition of antineoplas- tic agent emetogenicity-state of the art. Support Care Cancer 19:S43–S47 Guyatt G, Gutterman D, Baumann MH et al 2006 Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129:174–181 Hählen K, Quintana E, Pinkerton CR, Cedar E 1995 A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexametha- sone in the prevention of ifosfamide-induced emesis in children. J Pediatr 126:309–313 Hasler S, Hirt A, Ridolfi Luethy A et al 2008 Safety of ondansetron loading doses in children with cancer. Support Care Cancer 16:469–475 Herrstedt J 2008 Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 5:32–43 Hesketh PJ 1994 Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT 3 receptor antagonists. Support Care Cancer 2:286–292 Hesketh PJ 2008 Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494 Hesketh PJ, Kris MG, Grunberg SM et al 1997 Proposal for classifying the acute emetogenicity of cancer che- motherapy. J Clin Oncol 15:103–109 Hesketh PJ, Grunberg SM, Gralla RJ et al 2003 The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multi-national, randomized, double-blind, placebo- controlled trial in patients receiving high-dose